In a previous meta-analysis conducted by Yin et al. on bezafibrate, the most extensively investigated PPAR agonist for PBC, a significant reduction in ALT levels (MD = −10.24 IU/L, p = 0.00001) [22] was reported. This evidence concerns the gene GPT and primary biliary cholangitis.